Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Roux, Perrine ^a,b,c   Castro, Daniela Rojas ^d,e   Ndiaye, Khadim ^a,b,c   Debrus, Marie ^e   Protopopescu, Camélia ^a,b,c   Gall, Jean Marie Le ^d   Haas, Aurélie ^d   Mora, Marion ^a,b,c   Spire, Bruno ^a,b,c,d   Suzan Monti, Marie ^a,b,c,d   Carrieri, Patrizia ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d AIDES ^*  (France)

^e République Démocratique du Congo   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; MORPHINE SULFATE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HEALTH EDUCATION; HEPATITIS C RAPID TEST; HIGH RISK BEHAVIOR; HIGH SCHOOL GRADUATE; HOUSING; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK REDUCTION; VIRUS TRANSMISSION; CLINICAL TRIAL; COMMUNITY PARTICIPATION; COMPLICATION; CONTROLLED CLINICAL TRIAL; FRANCE; HARM REDUCTION; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C; ISOLATION AND PURIFICATION; MASS SCREENING; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VIROLOGY;

ADULT; COMMUNITY PARTICIPATION; FEMALE; FRANCE; HARM REDUCTION; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MASS SCREENING; NEEDLE-EXCHANGE PROGRAMS; PATIENT EDUCATION AS TOPIC; RISK REDUCTION BEHAVIOR; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84976427889     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157062     Document Type: Article

References (30)

1. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005, 100:1690-1700. PMID: 16277629
2. Degenhardt L, Mathers BM, Wirtz AL, Wolfe D, Kamarulzaman A, Carrieri MP, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy 2014, 25:53-60. doi: 10.1016/j.drugpo.2013.08.004 PMID: 24113623
3. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583. doi: 10.1016/S0140-6736(11)61097-0 PMID: 21802134
4. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioiddependent people: cohort study. Addiction 2011, 106:2186-2192. doi: 10.1111/j.1360-0443.2011. 03575.x PMID: 21749525
5. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012, 107:1984-1995. doi: 10.1111/j.1360-0443.2012.03932.x PMID: 22564041
6. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014, 9:e103345. doi: 10.1371/journal.pone.0103345 PMID: 25068274
7. McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ. Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. Epidemiol Infect 2014, 142:200-207. doi: 10.1017/S0950268813000617 PMID: 23522183
8. McDonald SA, Hutchinson SJ, Mills PR, Bird SM, Robertson C, Dillon JF, et al. Diagnosis of hepatitis C virus infection in Scotland's injecting drug user population. Epidemiol Infect 2010, 138:393-402. doi: 10.1017/S0950268809990616 PMID: 19723361
9. Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis 2014, 58:755-761. doi: 10.1093/cid/cit938 PMID: 24363333
10. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008, 93:141-147. PMID: 17997050
11. Roux P, Le Gall JM, Debrus M, Protopopescu C, Demoulin B, Lions C, et al. Innovative communitybased educational face-to-face intervention to reduce HIV, HCV and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. Addiction 2015.
12. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992, 87:733-742. PMID: 1591524
13. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007, 31:1208-1217. PMID: 17451397
14. Fry CL, Lintzeris N. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Addiction 2003, 98:171-178. PMID: 12534421
15. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013, 57 Suppl 2:S32-38. doi: 10.1093/cid/cit300 PMID: 23884063
16. Whelan C, Chambers C, Chan M, Thomas S, Ramos G, Hwang SW. Why do homeless people use a mobile health unit in a country with universal health care? J Prim Care Community Health 2010, 1:78-82. doi: 10.1177/2150131910372233 PMID: 23804366
17. Currie LB, Patterson ML, Moniruzzaman A, McCandless LC, Somers JM. Examining the relationship between health-related need and the receipt of care by participants experiencing homelessness and mental illness. BMC Health Serv Res 2014, 14:404. doi: 10.1186/1472-6963-14-404 PMID: 25230990
18. Daiski I. The health bus: healthcare for marginalized populations. Policy Polit Nurs Pract 2005, 6:30-38. PMID: 16443957
19. Hastings J, Zulman D, Wali S. UCLA mobile clinic project. J Health Care Poor Underserved 2007, 18:744-748. PMID: 17982203
20. Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, et al. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. J Epidemiol Community Health 2015, 69:599-603. doi: 10.1136/jech-2014-205070 PMID: 25870164
21. EMCDDA. Drug treatment overview for France. In: European Monitoring Centre for Drugs and Drug Addiction; 2013.
22. Benyamina A. The current status of opioid maintenance treatment in France: a survey of physicians, patients, and out-of-treatment opioid users. Int J Gen Med 2014, 7:449-457. doi: 10.2147/IJGM. S61014 PMID: 25228817
23. Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013, 13:9. doi: 10.1186/ 1471-2334-13-9 PMID: 23298178
24. Rotily M, Loubiere S, Prudhomme J, Portal I, Tran A, Hofliger P, et al. [Factors related to screening of hepatitis C virus in general medicine]. Gastroenterol Clin Biol 2002, 26:261-269. PMID: 11981471
25. Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, et al. Engaging HIV-HCV coinfected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res 2012, 12:59. doi: 10.1186/1472-6963-12-59 PMID: 22409788
26. Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012, 19:836-842. doi: 10.1111/j.1365-2893.2012.01648.x PMID: 23121361
27. Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 2014, 34:1198-1206. doi: 10.1111/liv.12370 PMID: 24164865
28. Fischer B, Rehm J, Patra J, Kalousek K, Haydon E, Tyndall M, et al. Crack across Canada: Comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction 2006, 101:1760-1770. PMID: 17156175
29. Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 2009, 9:113. doi: 10.1186/1471-2334-9-113 PMID: 19607712
30. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998, 51:253-263; discussion 267-258. PMID: 9787998